Novartis’ Enablex Given Green Light for Clinical Trials By China’s SFDA
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's State FDA has officially accepted BMP Sunstone's clinical trial application for Novartis' Enablex (darifenacin), the company announced May 6.